Methods	Six-week randomised, double-blind multicentre study.
Participants	Outpatients fulfilling DSM-IV criteria for unipolar major depressive disorder, with a score of at least 14 on the HDRS-21. Age range: 18-62 years old. Exclusion criteria: diagnosis of amood disorder to a secondary general medical condition, bipolar disorder, substance abuse, history of prior treatment with sertraline or fluoxetine. For patients with a history of substance abuse a period of 30 days of sobriety was required prior to study entry
Interventions	Fluoxetine: 18 participants. Sertraline (50 mg): 17 participants. Sertraline (100 mg): 17 participants. Fluoxetine dose: 20 mg/day. Lorazepam (0.5 mg) was allowed.
Outcomes	Primary outcome: a HDRS score of maximum 7 or a CGI score of maximum 2 at endpoint (remission)
Notes	Funding: by industry
Risk of bias
Item	Authors’ judgement	Description
Allocation concealment?	Unclear	B - Unclear